This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

It would behoove more Americans to learn how consistent seafood consumption has strong potential to ward off coronary disease ...

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

The GLP-1 Exit Plan by Holli Bradish-Lane Holli Bradish-Lane, founder of Iron Crucible Health Coaching, is making waves in ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Hims & Hers Health Inc.'s stock booked record losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth ...